SEARCH

SEARCH BY CITATION

References

  • Ashkenazi, A. (2002) Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nature Reviews Cancer, 2, 420430.
  • Ashkenazi, A. & Dixit, V.M. (1998) Death receptors: signaling and modulation. Science, 281, 13051308.
  • Bratton, S.B., MacFarlane, M., Cain, K. & Cohen, G.M. (2000) Protein complexes activate distinct caspase cascades in death receptor and stress-induced apoptosis. Experimental Cell Research, 256, 2733.
  • Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P. & Watier, H. (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood, 99, 754758.
  • Chuntharapai, A., Dodge, K., Grimmer, K., Schroeder, K., Marsters, S.A., Koeppen, H., Ashkenazi, A. & Kim, K.J. (2001) Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. Journal of Immunology, 166, 48914898.
  • Clodi, K., Wimmer, D., Li, Y., Goodwin, R., Jaeger, U., Mann, G., Gadner, H. & Younes, A. (2000) Expression of tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptors and sensitivity to TRAIL-induced apoptosis in primary B-cell acute lymphoblastic leukaemia cells. British Journal of Haematology, 111, 580586.
  • Hao, C., Song, J.H., Hsi, B., Lewis, J., Song, D.K., Petruk, K.C., Tyrrell, D.L. & Kneteman, N.M. (2004) TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice. Cancer Research, 64, 85028506.
  • Inoue, S., MacFarlane, M., Harper, N., Wheat, L.M., Dyer, M.J. & Cohen, G.M. (2004) Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death and Differentiation, 11, S193S206.
  • Inoue, S., Mai, A., Dyer, M.J. & Cohen, G.M. (2006) Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Research, 66, 67856792.
  • Inoue, S., Riley, J., Gant, T.W., Dyer, M.J. & Cohen, G.M. (2007) Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa. Leukemia, 21, 17731782.
  • Kelley, R.F., Totpal, K., Lindstrom, S.H., Mathieu, M., Billeci, K., Deforge, L., Pai, R., Hymowitz, S.G. & Ashkenazi, A. (2005) Receptor-selective mutants of Apoptosis-inducing ligand 2L/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. Journal of Biological Chemistry, 280, 22052212.
  • Kono, K., Takahashi, A., Ichihara, F., Sugai, H., Fujii, H. & Matsumoto, Y. (2002) Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer. Cancer Research, 62, 58135817.
  • Koschny, R., Walczak, H. & Ganten, T.M. (2007) The promise of TRAIL-potential and risks of a novel anticancer therapy. Journal of Molecular Medicine, 85, 14321440.
  • Li, J., Zhang, Q., Johnson, J.A., Knee, D.A., Deveraux, Q., Nasoff, M.S. & Stover, D. (2007) Tumor-cell specific cytotoxic activity of LBY135, a novel anti-DR5 agonistic antibody. American Association of Cancer Research, Abstract # 4875.
  • MacFarlane, M., Harper, N., Snowden, R.T., Dyer, M.J., Barnett, G.A., Pringle, J.H. & Cohen, G.M. (2002) Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. Oncogene, 21, 68096818.
  • MacFarlane, M., Inoue, S., Kohlhaas, S.L., Majid, A., Harper, N., Kennedy, D.B., Dyer, M.J. & Cohen, G.M. (2005a) Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1. Cell Death and Differentiation, 12, 773782.
  • MacFarlane, M., Kohlhaas, S.L., Sutcliffe, M.J., Dyer, M.J. & Cohen, G.M. (2005b) TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. Cancer Research, 65, 1126511270.
  • Motoki, K., Mori, E., Matsumoto, A., Thomas, M., Tomura, T., Humphreys, R., Albert, V., Muto, M., Yoshida, H., Aoki, M., Tamada, T., Kuroki, R., Ishida, I., Ware, C.F. & Kataoka, S. (2005) Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2. Clinical Cancer Research, 11, 31263135.
  • Muhlenbeck, F., Schneider, P., Bodmer, J.L., Schwenzer, R., Hauser, A., Schubert, G., Scheurich, P., Moosmayer, D., Tschopp, J. & Wajant, H. (2000) The tumor necrosis factor-related apoptosis-inducing ligand receptors TRAIL-R1 and TRAIL-R2 have distinct cross-linking requirements for initiation of apoptosis and are non-redundant in JNK activation. Journal of Biological Chemistry, 275, 3220832213.
  • Peter, M.E. & Krammer, P.H. (2003) The CD95(APO-1/Fas) DISC and beyond. Cell Death and Differentiation, 10, 2635.
  • Pukac, L., Kanakaraj, P., Humphreys, R., Alderson, R., Bloom, M., Sung, C., Riccobene, T., Johnson, R., Fiscella, M., Mahoney, A., Carrell, J., Boyd, E., Yao, X.T., Zhang, L., Zhong, L., Von Kerczek, A., Shepard, L., Vaughan, T., Edwards, B., Dobson, C., Salcedo, T. & Albert, V. (2005) HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. British Journal of Cancer, 92, 14301441.
  • Qian, D.Z., Kato, Y., Shabbeer, S., Wei, Y., Verheul, H.M., Salumbides, B., Sanni, T., Atadja, P. & Pili, R. (2006) Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clinical Cancer Research, 12, 634642.
  • Snell, V., Clodi, K., Zhao, S., Goodwin, R., Thomas, E.K., Morris, S.W., Kadin, M.E., Cabanillas, F., Andreeff, M. & Younes, A. (1997) Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. British Journal of Haematology, 99, 618624.
  • Sun, X.M., MacFarlane, M., Zhuang, J., Wolf, B.B., Green, D.R. & Cohen, G.M. (1999) Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis. Journal of Biological Chemistry, 274, 50535060.
  • Thomas, L.R., Johnson, R.L., Reed, J.C. & Thorburn, A. (2004) The C-terminal tails of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas receptors have opposing functions in Fas-associated death domain (FADD) recruitment and can regulate agonist-specific mechanisms of receptor activation. Journal of Biological Chemistry, 279, 5247952486.
  • Wajant, H., Moosmayer, D., Wuest, T., Bartke, T., Gerlach, E., Schonherr, U., Peters, N., Scheurich, P. & Pfizenmaier, K. (2001) Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative. Oncogene, 20, 41014106.